Intradetrusor Triamcinolone Injection in the Management of Interstitial Cystitis/Bladder Pain Syndrome
Intradetrusor Triamcinolone Injection in the Management of Interstitial Cystitis/Bladder Pain Syndrome: Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Bilal Farhan, MD
- Phone Number: (409) 772-3137
- Email: bifarhan@utmb.edu
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- The University of Texas Medical Branch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must meet an appropriate diagnosis of IC from NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases)
- Patients must be female
- 18 years or older
- Have an official diagnosis of Interstitial Cystitis/Bladder Pain Syndrome
Exclusion Criteria:
- Patients who do not meet NIDDK inclusion criteria for Interstitial Cystitis as described above will not me enrolled in the study
- The presence of urinary tract or sexually transmitted infection (may be included once existing infection is treated and cleared)
- Pregnant women
- Patients who have the inability to consent on their own behalf
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Injection Group
|
Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic.
Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy.
Injections will be performed using a 17fr flexible cystoscope in the outpatient setting.
There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline.
The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip.
The patient may experience discomfort with cystoscopy and injections.
Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section.
This is estimated to take 30 minutes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
O'Leary-Sant Symptom Index; Problem Index; Pain, Urgency, Frequency Symptom Scale
Time Frame: One Year
|
Follow-up visits will occur every 4-to-6-weeks post-procedure as part of UTMB's standard of care.
Patients will be asked to fill out The O'Leary-Sant Symptom Index and Problem Index and the Pain, Urgency, Frequency Symptom Scale to quantify symptoms, which is not experimental.
No other procedures will occur for Visits #3 and onward.
Follow-up visits will continue for a maximum of 1 year
|
One Year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Urologic Diseases
- Urinary Bladder Diseases
- Disease
- Syndrome
- Cystitis
- Somatoform Disorders
- Cystitis, Interstitial
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
Other Study ID Numbers
Other Study ID Numbers
- 21-0227
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.